Tendyne Transcatheter Mitral Valve System
ABBOTT MEDICAL · Decision date Aug 31, 2026
What did the FDA decide?
FDA records P240042/S004 as a supplement to PMA P240042, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 31, 2026.
FDA approval order statement
to implement a supplier change for a component of the Tendyne Delivery System
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 31, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P240042/S004
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- NPU
- Decision code
- OK30
- Decision date
- Aug 31, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, mitral valve, percutaneously delivered.
- Applicant
- Abbott Medical
- Product code
- NPU
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P240042/S001 · Related supplement
Tendyne Transcatheter Mitral Valve
P240042/S002 · Related supplement
Tendyne Transcatheter Mitral Valve System
P240042/S004 received
Application receipt date recorded by FDA.
P240042/S003 · Related supplement
Tendyne Transcatheter Mitral Valve System
P240042/S004 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P240042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Tendyne Transcatheter Mitral ValveP240042/S001 | ABBOTT MEDICAL | PMA supplement | Jul 29, 2025 | FDA |
Tendyne Transcatheter Mitral Valve SystemP240042/S002 | ABBOTT MEDICAL | PMA supplement | Oct 4, 2025 | FDA |
Tendyne Transcatheter Mitral Valve SystemP240042/S003 | ABBOTT MEDICAL | PMA supplement | Aug 7, 2026 | FDA |
Explore the linked device profile
Other records with product code NPU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA supplement | Jul 29, 2026 | FDA | |
SAPIEN M3 Transcatheter Heart Valve (9880TFX29M)P250019/S005 | Edwards Lifesciences, LLC | PMA supplement | Jul 28, 2026 | FDA |
| Edwards Lifesciences, LLC | PMA supplement | Apr 16, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Mar 11, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Feb 19, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 177 County Rd. B E., St. Paul, MN, 55117
Sources and methodology
- Original FDA record: P240042/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
